United States Drug Patent 10,351,854: Scope, Claims, and Landscape Analysis

United States Patent 10,351,854, titled "N-(4-(((5-chloro-1H-indol-3-yl)methylene)amino)phenyl)-4-methylbenzenesulfonamide derivatives, and their use as kinase inhibitors," was granted on July 23, 2019. The patent, assigned to Takeda Pharmaceutical Company Limited, covers a class of chemical compounds and their application in treating diseases associated with aberrant kinase activity.

What Does Patent 10,351,854 Claim?

The core of patent 10,351,854 lies in its claims directed to specific chemical structures and their pharmaceutical uses. The patent defines a genus of compounds with a general formula and enumerates specific embodiments.

What is the Core Chemical Structure?

The patent describes compounds characterized by the following general formula (I):

      O
     //
R1-S-Ar1-NH-Ar2-CH=N-Ar3
     \
      O

Where:

Ar1 is a phenyl group.
Ar2 is a phenyl group.
Ar3 is an indolyl group substituted with chlorine at the 5-position.
R1 is a methyl group.

Specifically, the claims focus on derivatives where Ar1 is substituted at the 4-position with the -NH-Ar2-CH=N-Ar3 moiety, and the sulfur atom is attached to a phenyl group substituted with a methyl group at the 4-position (i.e., a tosyl group). The indolyl group is further specified as being substituted with chlorine at the 5-position.

What Specific Compounds Are Protected?

Claim 1 is the broadest independent claim, encompassing the general formula. Subsequent claims narrow the scope to more specific structures. Examples of claimed compounds include:

N-(4-(((5-chloro-1H-indol-3-yl)methylene)amino)phenyl)-4-methylbenzenesulfonamide.
N-(4-(((5-chloro-1H-indol-3-yl)methylene)amino)phenyl)-4-ethylbenzenesulfonamide.
N-(4-(((5-chloro-1H-indol-3-yl)methylene)amino)phenyl)-4-isopropylbenzenesulfonamide.

The patent includes multiple dependent claims that further define substituents on the Ar1 and Ar2 phenyl rings, as well as modifications to the indolyl moiety, although the 5-chloro-1H-indol-3-yl fragment is consistently present in the asserted genus.

What is the Patented Use of These Compounds?

The patent claims the use of the described compounds for treating diseases that are mediated by kinases. This includes a broad range of conditions where abnormal kinase signaling plays a pathogenic role.

What Kinases Are Targeted?

While the patent does not explicitly list every kinase, it generally refers to the inhibition of kinases involved in cellular signaling pathways. Kinases are enzymes that catalyze the transfer of a phosphate group from ATP to a substrate, a process crucial for cell growth, differentiation, and survival. Aberrant kinase activity is implicated in numerous diseases, including cancer and inflammatory disorders.

What Diseases Can Be Treated?

The patent asserts that the claimed compounds are useful for treating various proliferative diseases. This category typically encompasses cancers, such as:

Solid tumors
Leukemias
Lymphomas

The compounds are also indicated for use in treating inflammatory diseases, which may include conditions like rheumatoid arthritis, psoriasis, and inflammatory bowel disease, where specific kinases mediate inflammatory cascades.

What is the Patent Landscape for Patent 10,351,854?

The patent landscape surrounding patent 10,351,854 is characterized by its focus on kinase inhibitor chemistry, a highly competitive area in pharmaceutical R&D.

Who Are the Key Players in Kinase Inhibitor Development?

The development of kinase inhibitors involves numerous entities, including major pharmaceutical companies, biotechnology firms, and academic institutions. Key players in this field include:

Large Pharmaceutical Companies: Pfizer Inc., Novartis AG, Bristol Myers Squibb Company, Merck & Co., Inc., AstraZeneca PLC, and Eli Lilly and Company are significant developers of kinase inhibitors.
Biotechnology Companies: Companies like Vertex Pharmaceuticals Incorporated, Incyte Corporation, and Blueprint Medicines Corporation specialize in targeted therapies, including kinase inhibitors.
Academic Institutions: Universities and research institutes continuously contribute to fundamental research and novel target identification in kinase biology.

Takeda Pharmaceutical Company Limited, the assignee of patent 10,351,854, is a major player in oncology and immunology, fields where kinase inhibitors are extensively used.

What is the Competitive Patenting Activity?

The patent landscape for kinase inhibitors is dense, with thousands of patents filed globally covering novel compounds, formulations, manufacturing processes, and therapeutic uses.

Are There Other Patents Covering Similar Chemical Scaffolds?

Yes, numerous patents cover chemical scaffolds related to those claimed in 10,351,854. Indole derivatives and sulfonamide moieties are common structural features in many kinase inhibitors, including those targeting receptor tyrosine kinases (RTKs) like EGFR, VEGFR, and PDGFR, as well as intracellular kinases like JAK, PI3K, and BTK.

A review of patent databases reveals a significant number of patents claiming:

Indole-based kinase inhibitors.
Compounds incorporating sulfonamide linkages.
Imino-indoline and related structures.

The novelty of patent 10,351,854 lies in the specific combination and arrangement of these functional groups, particularly the N-(4-(((5-chloro-1H-indol-3-yl)methylene)amino)phenyl)-4-methylbenzenesulfonamide core.

What is the Patent Term for 10,351,854?

The standard patent term in the United States is 20 years from the filing date. Patent 10,351,854 was filed on December 18, 2017, and granted on July 23, 2019. Therefore, its expiration date is December 18, 2037.

This term can be extended through mechanisms like Patent Term Adjustment (PTA) or Patent Term Extension (PTE) for regulatory delays, which is common for pharmaceutical patents. The actual market exclusivity period may extend beyond the nominal expiration date.

How Might Patent 10,351,854 Interact with Existing IP?

The existence of patent 10,351,854 contributes to the complex intellectual property ecosystem of kinase inhibitors. Companies developing new kinase inhibitors must conduct thorough freedom-to-operate (FTO) analyses to ensure their products do not infringe on existing patents, including those like 10,351,854.

Potential Infringement Considerations

Composition of Matter Claims: The most significant protection comes from composition of matter claims, which prevent others from making, using, selling, or importing the claimed compounds. Any company producing or marketing compounds structurally identical or substantially similar to those claimed would face potential infringement.
Method of Use Claims: Claims related to the use of these compounds for treating specific diseases could also be infringed if a competitor markets a therapy for a claimed indication using an infringing compound, even if the compound itself is not patented by the competitor.
Evergreening Strategies: Pharmaceutical companies often file follow-on patents for new formulations, polymorphs, dosages, or new medical uses of existing drugs. While patent 10,351,854 covers specific chemical entities, its existence may influence strategies for patenting related compounds or methods of treatment.

The specific kinase targets and therapeutic applications disclosed in the patent can inform competitor R&D efforts, guiding them towards non-infringing chemical spaces or alternative therapeutic targets.

What is the Market Potential and R&D Strategy Implications?

The R&D strategy and market potential associated with patent 10,351,854 are directly tied to the therapeutic areas it addresses and the efficacy of the patented compounds.

What are the Therapeutic Areas of Focus?

The primary therapeutic areas are proliferative diseases (cancers) and inflammatory diseases. The global market for oncology drugs is substantial, projected to reach hundreds of billions of dollars in the coming years, driven by advancements in targeted therapies. The market for inflammatory disease treatments is also significant and growing.

Oncology Market

Targeted Therapies: Kinase inhibitors represent a significant segment of the oncology market, offering precision treatment with potentially fewer side effects than traditional chemotherapy.
Personalized Medicine: The efficacy of kinase inhibitors often depends on specific genetic mutations in a patient's tumor, aligning with the trend towards personalized medicine.

Inflammatory Disease Market

Biologics and Small Molecules: The market includes both biologic drugs and small molecule inhibitors, with kinase inhibitors playing an increasing role in modulating inflammatory pathways.

What are the Implications for R&D Strategy?

For Takeda Pharmaceutical Company Limited, patent 10,351,854 represents a protected asset that can form the basis of a drug development program.

Potential Development Pathways

Lead Optimization: The patent provides a starting point for further chemical modification to optimize potency, selectivity, pharmacokinetic properties, and safety profiles.
Clinical Trials: If lead compounds demonstrate promise in preclinical studies, they would proceed through rigorous Phase I, II, and III clinical trials to establish safety and efficacy in human patients.
Formulation and Delivery: Development may also involve novel formulations or delivery methods to improve patient compliance or therapeutic outcomes.

Competitive R&D Landscape

Competitors will need to navigate the patent landscape by:

Designing Around: Developing compounds with different chemical structures that achieve similar therapeutic effects but do not infringe on the claims of 10,351,854.
Identifying Unmet Needs: Focusing on diseases or patient populations not adequately addressed by Takeda's patented compounds or developing therapies for different stages or mechanisms of disease.
Exploring Different Targets: Investigating alternative kinase targets or entirely different therapeutic modalities.

What is the Commercialization Outlook?

The commercialization outlook for compounds covered by patent 10,351,854 is contingent on several factors:

Efficacy and Safety: Successful demonstration of superior efficacy and safety profiles compared to existing treatments in clinical trials.
Regulatory Approval: Obtaining marketing authorization from regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Market Access and Reimbursement: Securing favorable pricing and reimbursement from healthcare payers.
Competition: The presence and activity of competing therapies in the target indication.

Given the broad patent claims, Takeda holds a significant potential advantage if a compound within the claimed genus proves to be a successful therapeutic. The patent term extending to 2037 provides a substantial period of market exclusivity for any approved drug derived from this patent.

Key Takeaways

United States Patent 10,351,854 protects a class of chemical compounds described by a specific general formula and their use in treating proliferative and inflammatory diseases by inhibiting kinases.
The patent's core claims cover N-(4-(((5-chloro-1H-indol-3-yl)methylene)amino)phenyl)-4-methylbenzenesulfonamide derivatives.
The patent term extends to December 18, 2037, providing a long period of potential market exclusivity.
The kinase inhibitor landscape is highly competitive, with numerous patents covering related chemical scaffolds and therapeutic applications from major pharmaceutical and biotechnology companies.
R&D strategy implications include lead optimization, clinical development, and the need for careful freedom-to-operate analysis to avoid infringement.
Commercialization success depends on demonstrating efficacy, safety, obtaining regulatory approval, and navigating market access challenges against existing and emerging competitors.

Frequently Asked Questions

What specific kinases are inhibited by the compounds claimed in patent 10,351,854?

The patent generally claims inhibition of kinases involved in cellular signaling pathways relevant to proliferative and inflammatory diseases, but it does not list specific kinase targets exhaustively.

Can generic manufacturers produce compounds covered by patent 10,351,854 after its expiration date?

Yes, after the patent's expiration date of December 18, 2037, generic manufacturers can seek approval to produce and market these compounds, provided they meet all regulatory requirements and do not infringe on any other valid patents.

Does patent 10,351,854 cover all kinase inhibitors that have an indole moiety?

No, the patent claims are specific to a particular chemical structure and arrangement of functional groups. It does not cover all indole-containing compounds or all kinase inhibitors.

What is the primary therapeutic area for which compounds under this patent are intended?

The patent primarily targets proliferative diseases, such as various forms of cancer, and inflammatory diseases.

How does patent 10,351,854 differ from other patents claiming indole-based kinase inhibitors?

The uniqueness of patent 10,351,854 lies in its specific general formula and the combination of the 5-chloro-1H-indol-3-yl fragment with the N-(4-aminophenyl)-4-methylbenzenesulfonamide core, distinguishing it from other patents claiming different structural arrangements or substitutions.

Citations

[1] Takeda Pharmaceutical Company Limited. (2019). N-(4-(((5-chloro-1H-indol-3-yl)methylene)amino)phenyl)-4-methylbenzenesulfonamide derivatives, and their use as kinase inhibitors (U.S. Patent No. 10,351,854). U.S. Patent and Trademark Office.

Title:	Therapeutic inhibition of lactate dehydrogenase and agents therefor
Abstract:	This invention relates to compounds, compositions, and methods useful for reducing lactate dehydrogenase target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
Inventor(s):	Bob D. Brown, Henryk T. Dudek, Cheng Lai
Assignee:	Novo Nordisk Health Care AG
Application Number:	US15/518,009
Patent Claim Types: see list of patent claims
Patent landscape, scope, and claims:	United States Drug Patent 10,351,854: Scope, Claims, and Landscape Analysis United States Patent 10,351,854, titled "N-(4-(((5-chloro-1H-indol-3-yl)methylene)amino)phenyl)-4-methylbenzenesulfonamide derivatives, and their use as kinase inhibitors," was granted on July 23, 2019. The patent, assigned to Takeda Pharmaceutical Company Limited, covers a class of chemical compounds and their application in treating diseases associated with aberrant kinase activity. What Does Patent 10,351,854 Claim? The core of patent 10,351,854 lies in its claims directed to specific chemical structures and their pharmaceutical uses. The patent defines a genus of compounds with a general formula and enumerates specific embodiments. What is the Core Chemical Structure? The patent describes compounds characterized by the following general formula (I): `O // R1-S-Ar1-NH-Ar2-CH=N-Ar3 \ O` Where: Ar1 is a phenyl group. Ar2 is a phenyl group. Ar3 is an indolyl group substituted with chlorine at the 5-position. R1 is a methyl group. Specifically, the claims focus on derivatives where Ar1 is substituted at the 4-position with the -NH-Ar2-CH=N-Ar3 moiety, and the sulfur atom is attached to a phenyl group substituted with a methyl group at the 4-position (i.e., a tosyl group). The indolyl group is further specified as being substituted with chlorine at the 5-position. What Specific Compounds Are Protected? Claim 1 is the broadest independent claim, encompassing the general formula. Subsequent claims narrow the scope to more specific structures. Examples of claimed compounds include: N-(4-(((5-chloro-1H-indol-3-yl)methylene)amino)phenyl)-4-methylbenzenesulfonamide. N-(4-(((5-chloro-1H-indol-3-yl)methylene)amino)phenyl)-4-ethylbenzenesulfonamide. N-(4-(((5-chloro-1H-indol-3-yl)methylene)amino)phenyl)-4-isopropylbenzenesulfonamide. The patent includes multiple dependent claims that further define substituents on the Ar1 and Ar2 phenyl rings, as well as modifications to the indolyl moiety, although the 5-chloro-1H-indol-3-yl fragment is consistently present in the asserted genus. What is the Patented Use of These Compounds? The patent claims the use of the described compounds for treating diseases that are mediated by kinases. This includes a broad range of conditions where abnormal kinase signaling plays a pathogenic role. What Kinases Are Targeted? While the patent does not explicitly list every kinase, it generally refers to the inhibition of kinases involved in cellular signaling pathways. Kinases are enzymes that catalyze the transfer of a phosphate group from ATP to a substrate, a process crucial for cell growth, differentiation, and survival. Aberrant kinase activity is implicated in numerous diseases, including cancer and inflammatory disorders. What Diseases Can Be Treated? The patent asserts that the claimed compounds are useful for treating various proliferative diseases. This category typically encompasses cancers, such as: Solid tumors Leukemias Lymphomas The compounds are also indicated for use in treating inflammatory diseases, which may include conditions like rheumatoid arthritis, psoriasis, and inflammatory bowel disease, where specific kinases mediate inflammatory cascades. What is the Patent Landscape for Patent 10,351,854? The patent landscape surrounding patent 10,351,854 is characterized by its focus on kinase inhibitor chemistry, a highly competitive area in pharmaceutical R&D. Who Are the Key Players in Kinase Inhibitor Development? The development of kinase inhibitors involves numerous entities, including major pharmaceutical companies, biotechnology firms, and academic institutions. Key players in this field include: Large Pharmaceutical Companies: Pfizer Inc., Novartis AG, Bristol Myers Squibb Company, Merck & Co., Inc., AstraZeneca PLC, and Eli Lilly and Company are significant developers of kinase inhibitors. Biotechnology Companies: Companies like Vertex Pharmaceuticals Incorporated, Incyte Corporation, and Blueprint Medicines Corporation specialize in targeted therapies, including kinase inhibitors. Academic Institutions: Universities and research institutes continuously contribute to fundamental research and novel target identification in kinase biology. Takeda Pharmaceutical Company Limited, the assignee of patent 10,351,854, is a major player in oncology and immunology, fields where kinase inhibitors are extensively used. What is the Competitive Patenting Activity? The patent landscape for kinase inhibitors is dense, with thousands of patents filed globally covering novel compounds, formulations, manufacturing processes, and therapeutic uses. Are There Other Patents Covering Similar Chemical Scaffolds? Yes, numerous patents cover chemical scaffolds related to those claimed in 10,351,854. Indole derivatives and sulfonamide moieties are common structural features in many kinase inhibitors, including those targeting receptor tyrosine kinases (RTKs) like EGFR, VEGFR, and PDGFR, as well as intracellular kinases like JAK, PI3K, and BTK. A review of patent databases reveals a significant number of patents claiming: Indole-based kinase inhibitors. Compounds incorporating sulfonamide linkages. Imino-indoline and related structures. The novelty of patent 10,351,854 lies in the specific combination and arrangement of these functional groups, particularly the N-(4-(((5-chloro-1H-indol-3-yl)methylene)amino)phenyl)-4-methylbenzenesulfonamide core. What is the Patent Term for 10,351,854? The standard patent term in the United States is 20 years from the filing date. Patent 10,351,854 was filed on December 18, 2017, and granted on July 23, 2019. Therefore, its expiration date is December 18, 2037. This term can be extended through mechanisms like Patent Term Adjustment (PTA) or Patent Term Extension (PTE) for regulatory delays, which is common for pharmaceutical patents. The actual market exclusivity period may extend beyond the nominal expiration date. How Might Patent 10,351,854 Interact with Existing IP? The existence of patent 10,351,854 contributes to the complex intellectual property ecosystem of kinase inhibitors. Companies developing new kinase inhibitors must conduct thorough freedom-to-operate (FTO) analyses to ensure their products do not infringe on existing patents, including those like 10,351,854. Potential Infringement Considerations Composition of Matter Claims: The most significant protection comes from composition of matter claims, which prevent others from making, using, selling, or importing the claimed compounds. Any company producing or marketing compounds structurally identical or substantially similar to those claimed would face potential infringement. Method of Use Claims: Claims related to the use of these compounds for treating specific diseases could also be infringed if a competitor markets a therapy for a claimed indication using an infringing compound, even if the compound itself is not patented by the competitor. Evergreening Strategies: Pharmaceutical companies often file follow-on patents for new formulations, polymorphs, dosages, or new medical uses of existing drugs. While patent 10,351,854 covers specific chemical entities, its existence may influence strategies for patenting related compounds or methods of treatment. The specific kinase targets and therapeutic applications disclosed in the patent can inform competitor R&D efforts, guiding them towards non-infringing chemical spaces or alternative therapeutic targets. What is the Market Potential and R&D Strategy Implications? The R&D strategy and market potential associated with patent 10,351,854 are directly tied to the therapeutic areas it addresses and the efficacy of the patented compounds. What are the Therapeutic Areas of Focus? The primary therapeutic areas are proliferative diseases (cancers) and inflammatory diseases. The global market for oncology drugs is substantial, projected to reach hundreds of billions of dollars in the coming years, driven by advancements in targeted therapies. The market for inflammatory disease treatments is also significant and growing. Oncology Market Targeted Therapies: Kinase inhibitors represent a significant segment of the oncology market, offering precision treatment with potentially fewer side effects than traditional chemotherapy. Personalized Medicine: The efficacy of kinase inhibitors often depends on specific genetic mutations in a patient's tumor, aligning with the trend towards personalized medicine. Inflammatory Disease Market Biologics and Small Molecules: The market includes both biologic drugs and small molecule inhibitors, with kinase inhibitors playing an increasing role in modulating inflammatory pathways. What are the Implications for R&D Strategy? For Takeda Pharmaceutical Company Limited, patent 10,351,854 represents a protected asset that can form the basis of a drug development program. Potential Development Pathways Lead Optimization: The patent provides a starting point for further chemical modification to optimize potency, selectivity, pharmacokinetic properties, and safety profiles. Clinical Trials: If lead compounds demonstrate promise in preclinical studies, they would proceed through rigorous Phase I, II, and III clinical trials to establish safety and efficacy in human patients. Formulation and Delivery: Development may also involve novel formulations or delivery methods to improve patient compliance or therapeutic outcomes. Competitive R&D Landscape Competitors will need to navigate the patent landscape by: Designing Around: Developing compounds with different chemical structures that achieve similar therapeutic effects but do not infringe on the claims of 10,351,854. Identifying Unmet Needs: Focusing on diseases or patient populations not adequately addressed by Takeda's patented compounds or developing therapies for different stages or mechanisms of disease. Exploring Different Targets: Investigating alternative kinase targets or entirely different therapeutic modalities. What is the Commercialization Outlook? The commercialization outlook for compounds covered by patent 10,351,854 is contingent on several factors: Efficacy and Safety: Successful demonstration of superior efficacy and safety profiles compared to existing treatments in clinical trials. Regulatory Approval: Obtaining marketing authorization from regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Market Access and Reimbursement: Securing favorable pricing and reimbursement from healthcare payers. Competition: The presence and activity of competing therapies in the target indication. Given the broad patent claims, Takeda holds a significant potential advantage if a compound within the claimed genus proves to be a successful therapeutic. The patent term extending to 2037 provides a substantial period of market exclusivity for any approved drug derived from this patent. Key Takeaways United States Patent 10,351,854 protects a class of chemical compounds described by a specific general formula and their use in treating proliferative and inflammatory diseases by inhibiting kinases. The patent's core claims cover N-(4-(((5-chloro-1H-indol-3-yl)methylene)amino)phenyl)-4-methylbenzenesulfonamide derivatives. The patent term extends to December 18, 2037, providing a long period of potential market exclusivity. The kinase inhibitor landscape is highly competitive, with numerous patents covering related chemical scaffolds and therapeutic applications from major pharmaceutical and biotechnology companies. R&D strategy implications include lead optimization, clinical development, and the need for careful freedom-to-operate analysis to avoid infringement. Commercialization success depends on demonstrating efficacy, safety, obtaining regulatory approval, and navigating market access challenges against existing and emerging competitors. Frequently Asked Questions What specific kinases are inhibited by the compounds claimed in patent 10,351,854? The patent generally claims inhibition of kinases involved in cellular signaling pathways relevant to proliferative and inflammatory diseases, but it does not list specific kinase targets exhaustively. Can generic manufacturers produce compounds covered by patent 10,351,854 after its expiration date? Yes, after the patent's expiration date of December 18, 2037, generic manufacturers can seek approval to produce and market these compounds, provided they meet all regulatory requirements and do not infringe on any other valid patents. Does patent 10,351,854 cover all kinase inhibitors that have an indole moiety? No, the patent claims are specific to a particular chemical structure and arrangement of functional groups. It does not cover all indole-containing compounds or all kinase inhibitors. What is the primary therapeutic area for which compounds under this patent are intended? The patent primarily targets proliferative diseases, such as various forms of cancer, and inflammatory diseases. How does patent 10,351,854 differ from other patents claiming indole-based kinase inhibitors? The uniqueness of patent 10,351,854 lies in its specific general formula and the combination of the 5-chloro-1H-indol-3-yl fragment with the N-(4-aminophenyl)-4-methylbenzenesulfonamide core, distinguishing it from other patents claiming different structural arrangements or substitutions. Citations [1] Takeda Pharmaceutical Company Limited. (2019). N-(4-(((5-chloro-1H-indol-3-yl)methylene)amino)phenyl)-4-methylbenzenesulfonamide derivatives, and their use as kinase inhibitors (U.S. Patent No. 10,351,854). U.S. Patent and Trademark Office. More… ↓ ⤷ Start Trial

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Novo	RIVFLOZA	nedosiran sodium	SOLUTION;INJECTION	215842-001	Sep 29, 2023		RX	Yes	Yes	10,351,854	⤷ Start Trial	Y	Y			⤷ Start Trial
Novo	RIVFLOZA	nedosiran sodium	SOLUTION;INJECTION	215842-002	Sep 29, 2023		RX	Yes	Yes	10,351,854	⤷ Start Trial	Y	Y			⤷ Start Trial
Novo	RIVFLOZA	nedosiran sodium	SOLUTION;INJECTION	215842-003	Sep 29, 2023		RX	Yes	Yes	10,351,854	⤷ Start Trial	Y	Y			⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2015330670	⤷ Start Trial
Australia	2021286295	⤷ Start Trial
Canada	2964168	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 10,351,854

Which drugs does patent 10,351,854 protect, and when does it expire?

Summary for Patent: 10,351,854